Drugs For Schistosomiasis Market

Market Insights:

Schistosomiasis is an infection people acquire while coming into contact with the water-containing larva of schistosomes. The adult form of worms lives inside humans’ intestines and urinary tracts. According to the World Health Organization, nearly 200,000 people die annually from Schistosomiasis. The Drugs for the Schistosomiasis market are estimated to reach USD 103.4 million in 2027 from USD 73.4 million in 2020. The market is anticipated to grow at a CAGR of 5.6% during the forecast timeline.

Increasing Incidences of Water Contamination

Schistosomiasis is one of the most commonly found diseases in the world. Schistosomiasis prevalence is higher in tropical and sub-tropical regions across Asia, Africa, and Latin America. Parasitic worms mainly spread schistosomiasis. One of the most common ways of Schistosomiasis transmission and subsequent infection is being in contact with water wherein freshwater snails have released parasites in the form of the larva. Fresh water can also be contaminated by people already suffering from Schistosomiasis diseases. With the rising incidence of such contamination, transmission is taking place at a rapid pace.

Increase in Prevalence Rate

Schistosomiasis disease prevalence rate is quite high. Despite significant mortality, Schistosomiasis is one of the most neglected diseases in the world. Prevalence of Schistosomiasis is usually higher in underdeveloped countries on account of poverty, lack of hygiene, inadequate health awareness among people, etc. All over the world, more than 700 million people are vulnerable to being infected with Schistosomiasis. Over 200 million people have been infected with Schistosomiasis across 75 countries, and more than 60% of them have developed the disease.

Impact of COVID 19

COVID 19 has tumbled the Schistosomiasis drugs market with a sharp decline of over 10% in total revenue generation. Although market size shrunk in 2020, the demand for Schistosomiasis drugs has not declined. The Schistosomiasis market reported a negative growth rate because of the shutdown of production facilities, hurdles in the supply chain, lack of mobility, and stringent restrictions on cross-border trade. However, as the vaccination speed increases, production and demand are likely to be restored gradually.

The Middle East and Africa Region to Held Dominant Position

With a higher prevalence rate in the world, Middle East & Africa is one of the leading markets of drugs for Schistosomiasis. With more than 75% share in the total number of people generating infection of Schistosomiasis, Africa is the leading consumer of drugs for Schistosomiasis. Lack of health awareness, poverty, and socioeconomic reasons are resulted in neglect toward the risk of being infected with Schistosomiasis. Children and teenagers are most susceptible to the risk of Schistosomiasis development. On the contrary, despite the lower prevalence, the expenditure on drugs for Schistosomiasis is higher in North America and Europe. The Asia Pacific and Latin America also witness considerable Schistosomiasis prevalence next to Africa.

Praziquantel to Led the Market Growth    

There are a large number of drugs available for the treatment of Schistosomiasis. Some major drugs for Schistosomiasis include but are not limited to Biltricide, Artemisinins, Metrifonate, Oxamniquine, and Praziquantel. However, Praziquantel has been found to be the most effective drug for a broad spectrum of Schistosomiasis diseases to be treated with. It held over 25% share of total revenue generated by all drugs for Schistosomiasis in 2020.

The increasing number of schistosomiasis patients drives the global demand for Drugs for Schistosomiasis.

The improving healthcare facilities in developing countries around the world are increasing the detections of schistosomiasis patients. In addition, increasing pollution in rivers, lakes, and ponds in tropical and sub-tropical countries is breeding grounds for Schistosoma species that cause the infection. Nearly 700 million people live in endemic countries, and it increases the risk of infection. Africa and the Middle East account for a 42.1% share of the total revenue generated by the global Drugs for Schistosomiasis industry.

Research & Development is the Key to Success in the Market           

Some of the most renowned players operating in this industry include Bayer AG, Chandra Bhagat Pharma Ltd, EIPICO, Merck & Co Inc, Pfizer Inc, Par Pharmaceutical Inc, Samarth Pharma Pvt Ltd, Sanofi SA, Shin Poong Pharm Co Ltd, and Taj Pharmaceuticals Ltd. Key players are focusing on research & development as key to success in this industry. First, many players have generated a strong pipeline of drugs for Schistosomiasis. Secondly, market players are infiltrating the industry by developing a deep routed distribution network to reach end-users of the last mile.

Table of Content

1.Preface
1.1.Report Description
1.1.1.Purpose of the Report
1.1.2.Target Audience
1.1.3.USP and Key Offerings
1.2.Research Scope
1.3.Research Methodology
1.3.1.Phase I – Secondary Research
1.3.2.Phase II – Primary Research
1.3.3.Phase III – Expert Panel Review
1.3.4.Approach Adopted
1.3.4.1.Top-Down Approach
1.3.4.2.Bottom-Up Approach
1.3.5.Assumptions
1.4.Market Segmentation

2.Executive Summary
2.1.Market Snapshot: Global Drugs for Schistosomiasis Market

3.Market Dynamics & Factors Analysis
3.1.Introduction
3.1.1. Global Drugs for Schistosomiasis Market Value, 2015-2027, (US$ Bn)
3.2.Market Dynamics
3.2.1.Key Growth Trends
3.2.2.Major Industry Challenges
3.2.3.Key Growth Pockets
3.3.Attractive Investment Proposition, 2020
3.3.1.Drug Type
3.3.2.Application
3.3.3.Distribution Channel
3.3.4.Geography
3.3.5.Pipeline Analysis
3.3.6.Regulations
3.4.Porter’s Five Forces Analysis
3.4.1.Threat of New Entrants
3.4.2.Bargaining Power of Buyers/Consumers
3.4.3.Bargaining Power of Suppliers
3.4.4.Threat of Substitute Products
3.4.5.Intensity of Competitive Rivalry
3.5.Value Chain Analysis
3.6.Schistosomiasis Prevalence Rate by Region

4.Market Positioning of Key Players, 2020
4.1.Company market share of key players, 2020
4.2.Top 6 Players
4.3.Top 3 Players
4.4.Major Strategies Adopted by Key Players
4.5.Market Positioning of Key Players
4.6.Product Benchmarking
4.7.List of Key Distributors
4.8.Key Demographics

5.COVID 19 Impact Analysis
5.1.Global Drugs for Schistosomiasis Market Pre Vs Post COVID 19, 2019 – 2027
5.2.Impact on Import & Export
5.3.Impact on Demand & Supply

6.North America
6.1.North America Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
6.1.1.U.S.
6.1.2.Canada
6.1.3.Mexico
6.2.North America Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
6.2.1.Overview
6.2.2.Artemisinins
6.2.3.Biltricide
6.2.4.Corticosteroids
6.2.5.Metrifonate
6.2.6.Trioxolanes
6.2.7.Praziquantel
6.2.8.Oxamniquine
6.2.9.Others
6.3.North America Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
6.3.1.Overview
6.3.2.Schistosoma Guineensis
6.3.3.Schistosoma Haematobium
6.3.4.Schistosoma Intercalatum
6.3.5.Schistosoma Japonicum
6.3.6.Schistosoma Mansoni
6.3.7.Schistosoma Mekongi
6.4.North America Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
6.4.1.Overview
6.4.2.Hospital Pharmacy
6.4.3.Online Pharmacy
6.4.4.Retail Pharmacy

7.Europe
7.1.Europe Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
7.1.1.UK
7.1.2.France
7.1.3.Germany
7.1.4.Italy
7.1.5.Russia
7.1.6.Spain
7.1.7.Belgium
7.1.8.Netherland
7.1.9.Austria
7.1.10.Sweden
7.1.11.Poland
7.1.12.Denmark
7.1.13.Switzerland
7.1.14.Rest of Europe
7.2.Europe Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
7.2.1.Overview
7.2.2.Artemisinins
7.2.3.Biltricide
7.2.4.Corticosteroids
7.2.5.Metrifonate
7.2.6.Trioxolanes
7.2.7.Praziquantel
7.2.8.Oxamniquine
7.2.9.Others
7.3.Europe Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
7.3.1.Overview
7.3.2.Schistosoma Guineensis
7.3.3.Schistosoma Haematobium
7.3.4.Schistosoma Intercalatum
7.3.5.Schistosoma Japonicum
7.3.6.Schistosoma Mansoni
7.3.7.Schistosoma Mekongi
7.4.Europe Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
7.4.1.Overview
7.4.2.Hospital Pharmacy
7.4.3.Online Pharmacy
7.4.4.Retail Pharmacy

8.Asia Pacific
8.1.Asia Pacific Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
8.1.1.China
8.1.2.Japan
8.1.3.South Korea
8.1.4.India
8.1.5.Australia
8.1.6.New Zealand
8.1.7.Taiwan
8.1.8.Southeast Asia
8.1.9.Central Asia
8.1.10.Rest of Asia Pacific
8.2.Asia Pacific Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
8.2.1.Overview
8.2.2.Artemisinins
8.2.3.Biltricide
8.2.4.Corticosteroids
8.2.5.Metrifonate
8.2.6.Trioxolanes
8.2.7.Praziquantel
8.2.8.Oxamniquine
8.2.9.Others
8.3.Asia Pacific Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
8.3.1.Overview
8.3.2.Schistosoma Guineensis
8.3.3.Schistosoma Haematobium
8.3.4.Schistosoma Intercalatum
8.3.5.Schistosoma Japonicum
8.3.6.Schistosoma Mansoni
8.3.7.Schistosoma Mekongi
8.4.Asia Pacific Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
8.4.1.Overview
8.4.2.Hospital Pharmacy
8.4.3.Online Pharmacy
8.4.4.Retail Pharmacy

9.Latin America
9.1.Latin America Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
9.1.1.Brazil
9.1.2.Argentina
9.1.3.Peru
9.1.4.Chile
9.1.5.Colombia
9.1.6.Rest of Latin America
9.2.Latin America Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
9.2.1.Overview
9.2.2.Artemisinins
9.2.3.Biltricide
9.2.4.Corticosteroids
9.2.5.Metrifonate
9.2.6.Trioxolanes
9.2.7.Praziquantel
9.2.8.Oxamniquine
9.2.9.Others
9.3.Latin America Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
9.3.1.Overview
9.3.2.Schistosoma Guineensis
9.3.3.Schistosoma Haematobium
9.3.4.Schistosoma Intercalatum
9.3.5.Schistosoma Japonicum
9.3.6.Schistosoma Mansoni
9.3.7.Schistosoma Mekongi
9.4.Latin America Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
9.4.1.Overview
9.4.2.Hospital Pharmacy
9.4.3.Online Pharmacy
9.4.4.Retail Pharmacy

10.Middle East
10.1.Middle East Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
10.1.1.UAE
10.1.2.KSA
10.1.3.Israel
10.1.4.Turkey
10.1.5.Iran
10.1.6.Rest of Middle East
10.2.Middle East Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
10.2.1.Overview
10.2.2.Artemisinins
10.2.3.Biltricide
10.2.4.Corticosteroids
10.2.5.Metrifonate
10.2.6.Trioxolanes
10.2.7.Praziquantel
10.2.8.Oxamniquine
10.2.9.Others
10.3.Middle East Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
10.3.1.Overview
10.3.2.Schistosoma Guineensis
10.3.3.Schistosoma Haematobium
10.3.4.Schistosoma Intercalatum
10.3.5.Schistosoma Japonicum
10.3.6.Schistosoma Mansoni
10.3.7.Schistosoma Mekongi
10.4.Middle East Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
10.4.1.Overview
10.4.2.Hospital Pharmacy
10.4.3.Online Pharmacy
10.4.4.Retail Pharmacy

11.Africa
11.1.Africa Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
11.1.1.South Africa
11.1.2.Egypt
11.1.3.Nigeria
11.1.4.Rest of Africa
11.2.Africa Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
11.2.1.Overview
11.2.2.Artemisinins
11.2.3.Biltricide
11.2.4.Corticosteroids
11.2.5.Metrifonate
11.2.6.Trioxolanes
11.2.7.Praziquantel
11.2.8.Oxamniquine
11.2.9.Others
11.3.Africa Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
11.3.1.Overview
11.3.2.Schistosoma Guineensis
11.3.3.Schistosoma Haematobium
11.3.4.Schistosoma Intercalatum
11.3.5.Schistosoma Japonicum
11.3.6.Schistosoma Mansoni
11.3.7.Schistosoma Mekongi
11.4.Africa Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
11.4.1.Overview
11.4.2.Hospital Pharmacy
11.4.3.Online Pharmacy
11.4.4.Retail Pharmacy

12.Global
12.1.Global Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
12.1.1.Overview
12.1.2.Artemisinins
12.1.3.Biltricide
12.1.4.Corticosteroids
12.1.5.Metrifonate
12.1.6.Trioxolanes
12.1.7.Praziquantel
12.1.8.Oxamniquine
12.1.9.Others
12.2.Global Drugs for Schistosomiasis Market, By Application, 2015-2027 (US$ Bn)
12.2.1.Overview
12.2.2.Schistosoma Guineensis
12.2.3.Schistosoma Haematobium
12.2.4.Schistosoma Intercalatum
12.2.5.Schistosoma Japonicum
12.2.6.Schistosoma Mansoni
12.2.7.Schistosoma Mekongi
12.3.Global Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
12.3.1.Overview
12.3.2.Hospital Pharmacy
12.3.3.Online Pharmacy
12.3.4.Retail Pharmacy
12.3.5.

13.Company Profiles
13.1.Bayer AG
13.2.Chandra Bhagat Pharma Ltd
13.3.EIPICO
13.4.Merck & Co Inc
13.5.Pfizer Inc
13.6.Par Pharmaceutical Inc
13.7.Samarth Pharma Pvt Ltd
13.8.Sanofi SA
13.9.Shin Poong Pharm Co Ltd
13.10.Taj Pharmaceuticals Ltd

List of Figures

FIG. 1Global Drugs for Schistosomiasis Market: Research Methodology
FIG. 2Market Size Estimation – Top Down & Bottom up Approach
FIG. 3Global Drugs for Schistosomiasis Market Segmentation
FIG. 4Global Drugs for Schistosomiasis Market, by Drug Type 2019 (US$ Bn)
FIG. 5Global Drugs for Schistosomiasis Market, by Drug Schistosoma Haematobium019 (US$ Bn)
FIG. 6Global Drugs for Schistosomiasis Market, by Distribution Channel, 2019 (US$ Bn)
FIG. 7Global Drugs for Schistosomiasis Market, by Geography, 2019 (US$ Bn)
FIG. 8Attractive Investment Proposition, by Geography, 2019
FIG. 9Global Market Positioning of Key Drugs for Schistosomiasis Market Manufacturers, 2019
FIG. 10Global Drugs for Schistosomiasis Market Value Contribution, By Drug Type, 2019 & 2027 (Value %)
FIG. 11Global Drugs for Schistosomiasis Market, by Praziquantel, Value, 2015-2027 (US$ Bn)
FIG. 12Global Drugs for Schistosomiasis Market, by Artemisinins, Value, 2015-2027 (US$ Bn)
FIG. 13Global Drugs for Schistosomiasis Market, by Drug 3, Value, 2015-2027 (US$ Bn)
FIG. 14Global Drugs for Schistosomiasis Market, by Corticosteroids, Value, 2015-2027 (US$ Bn)
FIG. 15Global Drugs for Schistosomiasis Market, by Metrifonate, Value, 2015-2027 (US$ Bn)
FIG. 16Global Drugs for Schistosomiasis Market, by Others, Value, 2015-2027 (US$ Bn)
FIG. 17Global Drugs for Schistosomiasis Market Value Contribution, By Application, 2019 & 2027 (Value %)
FIG. 18Global Drugs for Schistosomiasis Market, by Schistosoma Mansoni, Value, 2015-2027 (US$ Bn)
FIG. 19Global Drugs for Schistosomiasis Market, by Schistosoma Haematobium, Value, 2015-2027 (US$ Bn)
FIG. 20Global Drugs for Schistosomiasis Market, by Schistosoma Guineensis, Value, 2015-2027 (US$ Bn)
FIG. 21Global Drugs for Schistosomiasis Market, by Schistosoma Japonicum, Value, 2015-2027 (US$ Bn)
FIG. 22Global Drugs for Schistosomiasis Market, by Schistosoma Mekongi, Value, 2015-2027 (US$ Bn)
FIG. 23Global Drugs for Schistosomiasis Market, by Others, Value, 2015-2027 (US$ Bn)
FIG. 24Global Drugs for Schistosomiasis Market Value Contribution, By Distribution Channel, 2019 & 2027 (Value %)
FIG. 25Global Drugs for Schistosomiasis Market, by Channel 1, Value, 2015-2027 (US$ Bn)
FIG. 26Global Drugs for Schistosomiasis Market, by Channel 2, Value, 2015-2027 (US$ Bn)
FIG. 27Global Drugs for Schistosomiasis Market, by Channel 3, Value, 2015-2027 (US$ Bn)
FIG. 28U.S. Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 29Rest of North America Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 30U.K. Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 31Germany Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 32France Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 33Rest of Europe Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 34Japan Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 35China Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 36India Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 37Rest of Asia Pacific Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
FIG. 38Middle East & Africa Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)
Latin America Drugs for Schistosomiasis Market, 2015-2027 (US$ Bn)

List of Tables

TABLE 1Market Snapshot: Global Drugs for Schistosomiasis Market
TABLE 2Global Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 3Global Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 4Global Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 5Global Drugs for Schistosomiasis Market, by Geography, 2015-2027 (US$ Bn)
TABLE 6North America Drugs for Schistosomiasis Market, by Drug Type 2015-2027 (US$ Bn)
TABLE 7North America Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 8North America Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 9North America Drugs for Schistosomiasis Market, by Country, 2015-2027 (US$ Bn)
TABLE 10Europe Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 11Europe Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 12Europe Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 13Europe Drugs for Schistosomiasis Market, by Country/Region, 2015-2027 (US$ Bn)
TABLE 14Asia Pacific Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 15Asia Pacific Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 16Asia Pacific Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 17Asia Pacific Drugs for Schistosomiasis Market, by Country/Region, 2015-2027 (US$ Bn)
TABLE 18Latin America Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 19Latin America Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 20Latin America Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 21Latin America Drugs for Schistosomiasis Market, by Country/Region, 2015-2027 (US$ Bn)
TABLE 22Middle East Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 23Middle East Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 24Middle East Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 25Middle East Drugs for Schistosomiasis Market, by Country/Region, 2015-2027 (US$ Bn)
TABLE 26Africa Drugs for Schistosomiasis Market, by Drug Type, 2015-2027 (US$ Bn)
TABLE 27Africa Drugs for Schistosomiasis Market, by Application, 2015-2027 (US$ Bn)
TABLE 28Africa Drugs for Schistosomiasis Market, by Distribution Channel, 2015-2027 (US$ Bn)
TABLE 29Africa Drugs for Schistosomiasis Market, by Country/Region, 2015-2027 (US$ Bn)
TABLE 30Bayer AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31Chandra Bhagat Pharma Ltd : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 EIPICO: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33Merck & Co Inc .: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34Pfizer Inc : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 35 Par Pharmaceutical Inc : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 36Samarth Pharma Pvt Ltd : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 37Sanofi SA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 38Shin Poong Pharm Co Ltd : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 39Taj Pharmaceuticals Ltd : Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 40Company 11: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 41Company 12: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments
TABLE 42Company 13: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments